Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Artemisinin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study Between Antimalarial and Anti-HIV Medications

NCT00266058
View directory record Official record
Conditions
HIV Infections, Malaria
Interventions
Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting Phase 2 Interventional

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

NCT04098744
View directory record Official record
Conditions
CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions
Artesunate vaginal insert, Placebo vaginal insert
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
25 Years to 100 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting Phase 2 Interventional

Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

NCT06206564
View directory record Official record
Conditions
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
Interventions
Artesunate ointment, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate

NCT02184637
View directory record Official record
Conditions
Malaria, Vivax
Interventions
Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

NCT06872112
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
Artesunate
Drug
Lead sponsor
Joseph C. Wu
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of Intravenous Artesunate

NCT00292929
View directory record Official record
Conditions
Malaria, Malaria, Cerebral
Interventions
Intravenous artesunate
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

NCT03100045
View directory record Official record
Conditions
HPV-Related Anal Intraepithelial Neoplasia, AIN2/3, Artesunate, Alternative Treatment, Anal Dysplasia, Precancerous Conditions, Human Papilloma Virus
Interventions
Artesunate Suppositories
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

NCT00697892
View directory record Official record
Conditions
HIV Infections, Malaria
Interventions
lopinavir/ritonavir, efavirenz, artemether/lumefantrine
Drug
Lead sponsor
Fran Aweeka
Other
Eligibility
21 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 28, 2026, 11:13 PM EDT
Terminated Phase 2 Interventional Results available

Novel Agents for Treatment of High-risk COVID-19 Positive Patients

NCT04374019
View directory record Official record
Conditions
COVID, Sars-CoV2
Interventions
Ivermectin, Camostat Mesilate, Artemesia annua, Artesunate
Drug · Dietary Supplement
Lead sponsor
Susanne Arnold
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

NCT06075264
View directory record Official record
Conditions
Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions
Artesunate ointment, Placebo ointment
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Safety of Intravenous Artesunate

NCT00292942
View directory record Official record
Conditions
Malaria, Malaria, Cerebral
Interventions
Intravenous Artesunate, Placebo
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 28, 2026, 11:13 PM EDT
Completed Not applicable Interventional Results available

Artemisinin to Reduce The Symptoms of Schizophrenia

NCT00753506
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Artemisinin, Identical looking placebo capsule
Dietary Supplement
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 28, 2026, 11:13 PM EDT
Active, not recruiting Phase 2 Interventional

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

NCT05555862
View directory record Official record
Conditions
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
Interventions
Artesunate, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 28, 2026, 11:13 PM EDT
Completed No phase listed Observational

Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria

NCT01228344
View directory record Official record
Conditions
Malaria
Interventions
Artemether-lumefantrine
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 28, 2026, 11:13 PM EDT
Recruiting Phase 2 Interventional

Study Evaluating the Efficacy and Safety of Artesunate

NCT06853184
View directory record Official record
Conditions
CMV Infection
Interventions
Artesunate, Ganciclovir (GCV)
Drug
Lead sponsor
Amivas Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 28, 2026, 11:13 PM EDT